Buoyed by strong third-quarter revenue growth, San Diego-based Nanogen is prepping its newly released NanoChip 400 System for US Food and Drug Administration approval and exploring new ways to license its IP portfolio, according to company officials.

The molecular diagnostics company will also make a follow-up investment in Jurilab, and look to channel its own and Jurilab's IP portfolio into licensing opportunities.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.